North America Immunoassays Market Outlook, 2031

Market Drivers

• Surge in companion diagnostics (CDx) for oncology: The rapid expansion of precision medicine in the United States and Canada is directly accelerating the integration of immunoassays into early-stage drug development and clinical validation. Pharmaceutical companies are heavily relying on immunoassay platforms to detect specific protein biomarkers and track anti-drug antibodies (ADAs). This is vital for determining patient eligibility for high-cost targeted biological therapies, such as monoclonal antibodies and immune checkpoint inhibitors. Because these therapies require definitive biomarker proof before insurance authorization, companion immunoassay tests are seeing a massive surge in clinical utility.
• Decentralization of diagnostic care and rise of CLIA-waiver pipelines: The healthcare delivery landscape in North America is transitioning away from centralized hospital laboratories toward retail clinics, urgent care centers, and physician offices. To capture this shift, manufacturers are intentionally designing compact immunoassay platforms to meet the strict criteria for a CLIA (Clinical Laboratory Improvement Amendments) waiver. By simplifying the user interface and reducing multi-step sample processing into closed-cartridge microfluidic systems, these devices can be operated by non-laboratory personnel.

Market Challenges

• Intensified competitive pressure from direct molecular (PCR/CRISPR) diagnostics: Immunoassays are facing severe technological encroachment from highly sensitive molecular and nucleic acid amplification technologies. In areas like infectious disease testing, where immunoassays historically held the majority of point-of-care market real estate, rapid molecular devices are becoming faster and cheaper. This presents a major obstacle for immunoassay platforms, as clinical buyers increasingly favor the inherently superior analytical sensitivity and definitive early-stage detection capabilities that PCR and emerging CRISPR-based diagnostic tools provide.
• Cross-reactivity and specificity vulnerabilities in advanced biomarker panels: As the clinical space demands increasingly complex diagnostic profiles, the fundamental biochemical limitation of antibody-antigen binding remains a significant hurdle. Structurally similar proteins, endogenous autoantibodies, or matrix interferences in complex patient samples frequently trigger cross-reactivity, leading to false-positive or false-negative results. This limitation is particularly challenging for newly discovered, low-abundance neurological and oncology biomarkers, where even minor analytic inaccuracies can misguide a clinical treatment pathway or force laboratories to rely on costly molecular confirmation methods.

Market Trends

• Transition from legacy ELISA to fully automated chemiluminescence (CLIA): High-throughput central and reference laboratories across North America are aggressively retiring traditional, manual ELISA protocols in favor of fully automated Chemiluminescence Immunoassay (CLIA) systems. CLIA platforms offer a far wider dynamic detection range, vastly superior signal intensity, and a significant reduction in hands-on technical time. To maintain their footprint, tier-one diagnostic providers are driving ecosystem lock-in by selling automated CLIA instruments under long-term, closed-loop consumable reagent contracts.
• Integration of microfluidic Lab-on-a-Chip designs: Immunoassay engineering is increasingly focusing on the digitalization of protein detection. By shrinking assay steps onto microfluidic chips, devices can process multiplex panels using micro-volumes of blood or saliva. Concurrently, platforms are adopting digital immunoassay techniques, such as single-molecule counting, which allows for sub-picogram detection of analytes. When paired with artificial intelligence algorithms in the assay reader, these next-generation platforms eliminate the visual subjectivity of traditional testing strips and provide objective, highly sensitive quantitative data.